APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 260 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 2.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,037,400 | -57.1% | 185,000 | +2.8% | 2.31% | -57.3% |
| Q2 2023 | $16,398,000 | +14.8% | 180,000 | -16.9% | 5.41% | +28.2% |
| Q1 2023 | $14,281,000 | -7.9% | 216,520 | -27.8% | 4.22% | -36.3% |
| Q4 2022 | $15,513,000 | -17.4% | 300,000 | +9.1% | 6.62% | +25.6% |
| Q3 2022 | $18,783,000 | +84.6% | 275,000 | +22.2% | 5.27% | -0.5% |
| Q2 2022 | $10,175,000 | -19.9% | 225,000 | -10.0% | 5.30% | +92.2% |
| Q1 2022 | $12,703,000 | -17.3% | 250,000 | -23.1% | 2.76% | -49.9% |
| Q4 2021 | $15,366,000 | +33.2% | 325,000 | -7.1% | 5.51% | +63.2% |
| Q3 2021 | $11,536,000 | +19.5% | 350,000 | +55.6% | 3.37% | +48.7% |
| Q1 2021 | $9,655,000 | -48.1% | 225,000 | -30.8% | 2.27% | -45.2% |
| Q4 2020 | $18,590,000 | -16.3% | 325,000 | -55.2% | 4.14% | -2.0% |
| Q4 2019 | $22,200,000 | +575.0% | 725,000 | +291.9% | 4.23% | +504.9% |
| Q3 2018 | $3,289,000 | -19.2% | 185,000 | 0.0% | 0.70% | -41.7% |
| Q2 2018 | $4,070,000 | – | 185,000 | – | 1.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AJU IB Investment Co., Ltd. | 1,114,962 | $63,776,000 | 24.13% |
| Octagon Capital Advisors LP | 548,374 | $31,367,000 | 10.87% |
| Ghost Tree Capital, LLC | 325,000 | $18,590,000 | 4.14% |
| Burrage Capital Management LLC | 81,357 | $4,654,000 | 3.55% |
| Aufman Associates Inc | 53,642 | $3,068,000 | 2.75% |
| ACUTA CAPITAL PARTNERS, LLC | 167,054 | $9,555,000 | 2.60% |
| Cormorant Asset Management, LP | 1,866,108 | $106,741,000 | 2.54% |
| Tri Locum Partners LP | 121,409 | $6,945,000 | 2.52% |
| venBio Partners LLC | 490,471 | $28,055,000 | 2.48% |
| HHLR ADVISORS, LTD. | 5,028,289 | $287,618,000 | 2.29% |